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Summary
No deficiency of human C-reactive protein (CRP), or even structural
polymorphism of the protein, has yet been reported so its physiological
role is not known. Here we show for the first time that CRP-deficient
mice are remarkably susceptible to Streptococcus pneumoniae infection
and are protected by reconstitution with isolated pure human CRP, or by
anti-pneumococcal antibodies. Autologous mouse CRP is evidently essen-
tial for innate resistance to pneumococcal infection before antibodies are
produced. Our findings are consistent with the significant association
between clinical pneumococcal infection and non-coding human CRP
gene polymorphisms which affect CRP expression. Deficiency or loss of
function variation in CRP may therefore be lethal at the first early-life
encounter with this ubiquitous virulent pathogen, explaining the invariant
presence and structure of CRP in human adults.
Keywords: anti-nuclear antibodies; C-reactive protein; host resistance;
mouse knockout; pneumococcal infection.
Introduction
The physiological functions of human C-reactive protein
(CRP), named for its interaction with pneumococcal
somatic C-polysaccharide, in which it specifically binds
the phosphocholine residues,1 are not known because no
deficiency or even structural variants of the protein have
been described. There are some extremely rare coding
polymorphisms of the CRP gene but the variant proteins
that they encode have not yet been reported. Such strict
structural conservation suggests that CRP may have a
function that is important for survival, potentially in
innate immunity. Injection of human CRP into mice at
the time of inoculation with virulent pneumococci con-
fers efficient protection against sepsis2–4 but administra-
tion of human CRP after inoculation of the bacteria does
not protect. Indeed, all patients with active pneumococcal
infections have greatly increased plasma CRP concentra-
tions and abundant circulating human CRP so it evi-
dently does not control established pneumococcal sepsis.
The gene coding and amino acid sequences, homopenta-
meric molecular assembly and calcium-dependent binding
of CRP to phosphocholine residues are all phylogenetically
conserved,5 for example mouse and human CRP share 71%
amino acid sequence identity. But baseline plasma concen-
tration, acute-phase behaviour, ligand precipitation,
Abbreviations: ANA, anti-nuclear antibody; CRP, C-reactive protein; Crp, mouse C-reactive protein gene; ES, embryonic stem;
SAA, serum amyloid A protein; SAP, serum amyloid P component
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agglutination and complement fixation vary widely
between the CRP of even closely related species.5 Hence,
functional observations across species or effects of human
CRP in mice cannot necessarily be reliably extrapolated to
humans, and the in vivo role of autologous CRP in host
defence has not previously been studied directly. We there-
fore created pure-line Crp gene-deleted C57BL/6 mice
using C57BL/6 embryonic stem (ES) cells and characterized
both their spontaneous phenotype and their responses to
various challenges relevant to suspected functions of CRP.
Material and methods
Gene deletion
Pure-line C57BL/6 Crp knockout mice were generated by
gene targeting in C57BL/6 ES cells and breeding with
C57BL/6 partners (see Supporting information, Fig. S1),
obviating any backcrossing. The CRP coding sequence was
precisely deleted along with the intron, and the selectable
marker was removed by FLP recombination in vivo, using
C57BL/6-Tg (CAG-Flpe) 2Arte mice transgenic for the FLP
recombinase (TaconicArtemis, model no. 7089). In the
resulting knockout allele, 891 bp of genomic sequence was
replaced by a 48-bp fragment containing a single FRT site.
All mice used for experiments were FLP.
Protein isolation and assays
Human CRP and serum amyloid P component (SAP),
> 99.9% pure and fully structurally and functionally
intact, were isolated by calcium-dependent affinity chro-
matography followed by specific solid-phase absorption
of contaminants and final gel filtration, as previously
described.6,7 Murine CRP (Life Diagnostics Inc., West
Chester, PA) and serum amyloid A protein (SAA; Tridelta
Development Ltd, Maynooth, Co. Kildare, Ireland) were
assayed by ELISA. Anti-nuclear antibody (ANA) was
detected by immunofluorescence as described.8
Bacterial infection
Streptococcus pneumoniae isolates were from clinical pneu-
mococcal infection cases or carriers, and from type cul-
tures, and were typed, cultured and quantified by standard
methods. Mouse infection studies were conducted as previ-
ously described9 in sex-matched and closely age-matched
groups of adult Crp knockout and wild-type control
C57BL/6 mice, and were humanely killed at 72 hr.
Study approval
All mouse experiments were fully compliant with UK
Home Office regulations, approved by the UCL Institu-
tional Review Board.
Results
Spontaneous phenotype of CRP-deficient mice
Homozygous Crp gene-deleted C57BL/6 mice developed
normally, were healthy and fertile, as previously indepen-
dently reported by Teupser et al.10 in their own strain of
C57BL/6 Crp knockout mice. No mouse CRP was detect-
able in the serum of our knockouts whereas the baseline
concentration in adult wild-type C57BL/6 mice was 5–
9 mg/l. At 24–48 hr after subcutaneous injection of 0.2 ml
2% weight/volume aqueous silver nitrate, a strong inflam-
matory stimulus, the circulating mouse CRP concentration
rose to a peak of 17 mg/l. Mean (SD) body weights at
weaning of pooled equal numbers of male and female mice
were: wild-type 10.2 (1.95) g, n = 26; Crp knockout 9.0
(2.76) g, n = 28, P = 0.0819 by Mann–Whitney U-test; at
7 weeks, wild-type 19.5 (2.41), n = 19; Crp knockout 18.6
(2.17), n = 19, P = 0.265 by Student’s t-test; at 10 weeks,
wild-type 21.4 (2.13), n = 20; Crp knockout 21.6 (2.03),
n = 18, P = 0.7025 by Student’s t-test. Adult males
weighed more than adult females at 7 and 10 weeks but
there was no significant difference between genotypes.
Lifespan was normal, with survival to 1100 days by
Kaplan–Meier analysis, n = 87 wild-type and 120 Crp
knockouts, P = 0.1768. Serum biochemistry (see Sup-
porting information, Fig. S2) and haematological param-
eters were not significantly different from wild-type
C57BL/6 mice. The baseline serum concentration of
mouse SAP, which is a major murine acute-phase reac-
tant,11 was very slightly higher in the Crp knockout
mice than in wild-type controls (Fig. 1a), consistent with
modestly up-regulated transcription of the Sap gene,
which is immediately adjacent and very closely related
to Crp, and/or increased efficiency of SAP protein secre-
tion. However, the serum concentrations of SAA, the
other sensitive murine acute-phase reactant, were not
increased (Fig. 1b), excluding an underlying pro-inflam-
matory state in the Crp knockouts.
Non-infectious challenges
C-reactive protein may have a role in preventing ANA
formation12–14 and spontaneous ANA production became
significantly greater among female but not male Crp
knockouts at 9 months of age (% mice with ANA posi-
tive at 1 : 80 serum dilution, n = 22 per group, P = 0.03
by Fisher’s exact test) and 12 months of age (P = 0.002,
n = 21) (Fig. 2). A Crp transgenic study is required to
determine whether this modest effect is indeed due to
CRP deficiency because the sle1 locus, which controls
ANA production, is adjacent to the Crp gene on distal
mouse chromosome 1. However, the response to immu-
nization with apoptotic thymocytes did not differ between
wild-type and Crp knockout mice (not shown).
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Consistent with our previous finding that transgenic
human CRP expression did not protect mice against the
toxicity of Gram-negative bacterial lipopolysaccharide,15
there was no significant difference between Crp knockouts
and wild-type mice in weight loss and clinical score or
lethality (Fig. 3) produced by intraperitoneal injection of
endotoxin at 10, 20 or 40 mg/kg. Local Shwartzman reac-
tions induced by intradermal injection of endotoxin from
Salmonella typhimurium, or from Haemophilus influenzae
strains with and without phosphocholine expression, also
did not differ between wild-type and Crp knockouts.
Pneumococcal infection
C-reactive protein-deficient mice were dramatically more
susceptible than age- and sex-matched wild-type C57BL/6
controls to lethal infection after intraperitoneal inocula-
tion of two independent clinical isolates of virulent type
6B S. pneumoniae (strains Tz7712-2 and RF200) (Fig. 4a,
b), with LD50 values of < 10 and about 10
6 organisms,
respectively (Fig. 4c). Lethality corresponded exactly with
viable bacterial counts in the blood at 20 hr after inocula-
tion; only mice with < 104 colony-forming units per ml
survived at 72 hr. The Crp knockout mice were also
much more susceptible to infection with type 27 S. pneu-
moniae which, unlike type 6B and most other pneumo-
cocci, have phosphocholine in the capsule16 (Fig.4d).
However, CRP-deficient mice were not more susceptible
to infection with pneumococcal strains RF206, serotype 1,
and RF32, serotype 19F, mucoid colonies of heavily
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Figure 1. Baseline concentrations of acute-phase proteins in sex and
age matched Crp knockout and control wild-type C57BL/6 mice.
Mean (SD), n = 7 per group, for (a) serum amyloid P component
(SAP) and (b) serum amyloid A protein (SAA).
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Figure 2. Spontaneous anti-nuclear antibody (ANA) production in
sex-matched and age-matched Crp knockout and control wild-type
C57BL/6 mice. Open columns, ANA-negative mice with titre < 1/80;
solid columns, ANA-positive mice with titre > 1/80. (a) 3 months of
age; (b) 6 months; (c) 9 months. Female Crp knockout mice had
significantly more ANA by Fisher’s exact test at 9 months (P = 0.03)
and at 12 months (P = 0.002).
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capsulated organisms isolated from blood cultures; or
strain Tz1003-2, serotype 6A, isolated from a carrier.
Intraperitoneal injection of just 3.5 lg of isolated pure
human CRP immediately before inoculation of Crp
knockouts with 103 colony-forming units of type 6B
S. pneumoniae, enabled survival at 72 hr of 80% (12/15)
of the animals, compared with only 7% (1/15) among
vehicle-only controls (P = 0.0001 by Fisher’s exact test)
(Fig. 5a), confirming that susceptibility is indeed due to
CRP deficiency. The very low abundance of mouse CRP
has so far prevented the isolation of sufficient intact pro-
tein for use in reconstitution studies. Importantly, human
SAP, which is structurally very similar to human CRP but
does not bind to phosphocholine or C-polysaccharide
under physiological solvent conditions,17 conferred no
protection. In contrast, mice that had been immunized
with dead pneumococci 4 weeks before the live challenge
were strongly protected (Fig. 5b), consistent with the
optimal protection provided by the T15 germ-line idio-
type anti-phosphocholine antibody.18 Autologous mouse
CRP is therefore required for innate resistance to pneu-
mococcal infection before sufficient specific antibodies are
produced, but can be replaced by isolated human CRP or
a previous anti-pneumococcal immune response.
Discussion
The pathogenic and host resistance mechanisms in pneu-
mococcal infection are controversial19,20 and complicated
by the variety and variability of pneumococci and by dif-
ferences between humans and experimental animals.
Pneumococcal phosphocholine expression is crucial for
respiratory tract colonization and for the virulence of
invasive infection.19,20 However, in vivo protection by
autologous CRP, the ubiquitous circulating phosphocho-
line-binding protein, has not previously been studied.
The dramatically increased susceptibility of Crp knockout
mice to types 6B and 27 pneumococci is therefore
remarkable.
Despite universal binding to free phosphocholine, there
are significant differences between the CRP of different
species in recognition of macromolecules such as C-poly-
saccharide and phospholipids in which the phosphocho-
line residues must be accessible and in the correct
stereochemistry. Native, non-aggregated human CRP does
not bind to the ubiquitous phosphocholine head groups
in the plasma membranes of healthy living cells, on native
low-density lipoprotein particles or on pure phosphatidyl
choline liposomes, but it avidly binds to membranes of
dead or damaged cells, modified low-density lipoproteins
or liposomes containing lysophosphatidyl choline.21–23
Even subtle differences in phosphocholine recognition
affect host resistance to pneumococci: antibody clones
arising during maturation of the anti-phosphocholine
response, which bind more avidly to p-nitrophenyl
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Figure 3. Lipopolysaccharide (LPS) lethality in sex-matched and
age-matched Crp knockout and control wild-type C57BL/6 mice.
There was no significant difference between survival of mice in the
two groups after administration of LPS at 10 mg/kg (a), 20 mg/kg
(b) or 40 mg/kg (c). The apparent trend to greater susceptibility in
the Crp knockout mice receiving 40 mg/kg, which did not achieve
statistical significance, is well within the typical variation in outcome
after administration of LPS to mice. Biological significance is not
supported by the fact that the knockouts were not more susceptible
than wild-type mice to smaller doses of LPS.
ª 2014 The Authors. Immunology published by John Wiley & Sons Ltd. Immunology, 142, 414–420 417
CRP and pneumococcal infection
phosphocholine or aminophenyl-phosphocholine than to
phosphocholine itself, are not protective.24 Furthermore,
pneumococcal surface protein A, the choline-binding bac-
terial protein which is a major pneumococcal virulence
factor, competes with CRP for binding to bacterial phos-
phocholine.25 Insufficient accessibility of phosphocholine
for binding by CRP therefore reduces or abolishes the
protective role of CRP in vivo and this is presumably why
we found that Crp knockout mice were not more suscep-
tible to infection with strains 1, 6A and 19F. Similarly, in
our preliminary experiments, CRP-deficient mice were
not more susceptible to Trypanosoma brucei, Plasmodium
berghei, Leishmania donovani and Brugia malayi (see Sup-
porting information, Fig. S3), despite the universal pres-
ence of phosphocholine in these parasites.26 None of
them are natural pathogens for mice and their phospho-
choline residues may not be accessible to, or recognized
by, mouse CRP. Also, regardless of the level of phospho-
choline expression by Haemophilus influenzae strains, we
could not establish infections with this organism in either
wild-type or Crp knockout mice.
Complement-dependent neutrophil phagocytosis and
killing of bacteria are essential for host defence against
pneumococci and are required for optimal protection of
mice by human CRP.19,20 C3 activation by pneumococci
in CRP-deficient mouse serum and its modest dose-depen-
dent enhancement by human CRP have been reported.25
However, our type 6B organisms activated C3 in both
Crp knockout and wild-type mouse serum. Hence, while
complement is necessary for optimal opsonophagocytosis
and bacterial killing, CRP may have other effects in host
defence. In particular, potent agglutination of bacteria by
CRP may alone be sufficient to reduce spread in vivo,
enabling more efficient neutrophil phagocytosis and killing
without having to invoke the involvement of Fc receptors,
cytokine production or dendritic cells, all of which have
previously been suggested.20 A key role for CRP in clump-
ing the first invading or inoculated bacteria is also consis-
tent with human CRP only protecting mice when given at
the time of infection and not thereafter, and with the fail-
ure of increased CRP production to control established
clinical pneumococcal infection in patients.
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Figure 4. Susceptibility to infection with Streptococcus pneumoniae. Kaplan–Meier survival analysis up to 72 hr after intraperitoneal inoculation
of Crp knockout mice and wild-type littermate controls with 105 colony-forming units (c.f.u.) per mouse of virulent S. pneumoniae type 6B,
isolated from two different clinical cases of pneumococcal pneumonia, (a), isolate Tz7712-2 and (b) isolate RF200. The results are representative
of three independent experiments. (c) Lethality at 72 hr of infection by intraperitoneal inoculation of different doses of virulent S. pneumoniae
type 6B isolate Tz7712-2 in Crp knockout mice (open bars) and wild-type littermate controls (closed bars) (three to five mice per group). Wild-
type mice were not tested with the lowest doses because they survived larger doses. For clarity, 0% survival is indicated by bars of 2%. The results
are representative of four independent experiments with doses of 103, 104 and 105 c.f.u.; for ethical reasons of animal welfare, doses of 101, 102,
106 and 107 c.f.u. were tested only in the experiment shown, as the results of further experiments clearly would not provide further information.
(d) Kaplan–Meier survival analysis up to 72 hr after intraperitoneal inoculation of Crp knockout mice and wild-type littermate controls with
5 9 104 c.f.u. per mouse of S. pneumoniae type 27 (strain HO 8452 0293) (single experiment). All P values are from log-rank tests.
ª 2014 The Authors. Immunology published by John Wiley & Sons Ltd. Immunology, 142, 414–420418
J. Paul Simons et al.
Streptococcus pneumoniae is not a natural pathogen for
mice and the conclusion, based on mouse CRP deficiency,
that human CRP has a necessary role in human host
defence against pneumococci must be cautious. However,
there is a convincing association between increased inci-
dence of pneumococcal sepsis and non-coding variants of
the human CRP gene, which cause lower baseline CRP
values.27–29 Upper respiratory tract carriage of pneumo-
cocci is very common in humans and these bacteria are
extremely virulent when they enter the tissues, so a criti-
cal role of human CRP in innate resistance is a compel-
ling explanation for the absence of any deficiency or even
structural variation in CRP. It is also consistent with the
high frequency of anti-phosphocholine idiotypes in the
germ-line antibody repertoire. Absence of human CRP or
loss of function variants may be lethal defects for neo-
nates or infants who encounter virulent phosphocholine-
bearing pneumococci when not adequately protected by
maternal or their own anti-phosphocholine antibodies.
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